An aortoenteric fistula (AEF) is defined as a conduit between an aortic aneurysm and the gastrointestinal (GI) tract ([@CIT0001]). Primary AEF (PAEF) exists in patients without a pre-existing abdominal aortic aneurysm (AAA) repair. On the other hand, secondary aortoenteric fistula (SAEF) occurs as a complication of an AAA repair ([@CIT0002]--[@CIT0005]). The abdominal aorta is more likely to be involved than the thoracic aorta (56 vs. 44%) ([@CIT0006]). In one-third of the cases, the abdominal aorta forms a channel with the duodenum ([@CIT0007]). This is secondary to the anatomical position of the third part of the duodenum, which lies between the superior mesenteric artery and the abdominal aorta ([@CIT0008]--[@CIT0010]). Rarely, conduit may involve ascending, transverse, sigmoid colon, or rectum ([@CIT0011]) ([Fig. 1](#F0001){ref-type="fig"}). A PAEF occurs in the setting of an unrepaired aortic aneurysm sac that erodes into the GI lumen, in the presence of predisposing factors such as atherosclerosis (60--80% of cases), infections (e.g., syphilis and tuberculosis), or mechanical stress (e.g., biliary calculi, ulcers, or radiation) ([@CIT0002], [@CIT0021], [@CIT0022]). Conversely, a SAEF occurs in patients with a previous AAA repair that may have a concurrent infection of the graft, hence leading to duodenal wall weakening and formation of a fistula or track. It is suggested that in the case of SAEF, the aortic pulsations, in some instances, may form a pseudoaneurysm. Each pulsation may produce shear stress on the GI mucosa, resulting in erosion ([@CIT0023]). The close proximity of the graft with the duodenum may hasten the migration of bowel flora. In most cases, the portal of entry is the suture line ([@CIT0024]). The infection may also be introduced at the time of AAA repair. The prosthetic graft may be colonized by *Staphylococcus epidermidis* -- a skin commensal known to form biofilm on prosthetic material. It may gain entry into the blood stream at the time of surgical repair, what is known as primary contamination ([@CIT0003]). Given the complicated surgical course and proximity of the bowel flora, it is not uncommon that blood and endovascular graft cultures may identify diverse microbes including Gram-positive organisms, Gram-negative organisms, and anaerobes (gut flora leading to secondary contamination). In some cases, no organism is identified on the culture ([@CIT0023]). Other organisms that have been isolated via different techniques include *Enterobacter*, *E. coli*, *Pseudomonas*, *Klebsiella*, *Streptococcus*, and methicillin-resistant *Staphylococcus aureus* (*MRSA*), *Listeria*, *Chlamydia*, *Clostridium*, *Propionibacterium*, and *Candida* ([@CIT0012]--[@CIT0014], [@CIT0025]--[@CIT0028]) ([Table 1](#T0001){ref-type="table"}).
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###### 

Secondary aortoenteric fistula: causative organism and clinical features

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------ ----------- ----------
  Causative organisms ([@CIT0002], [@CIT0012], [@CIT0013], [@CIT0015], [@CIT0017], [@CIT0018], [@CIT0023], [@CIT0029]--[@CIT0031])                                                 *Staphylococcus epidermidis*   12--21%     
  *Staphylococcus aureus* coagulase negative                                                                                                                                       9--41%                                     
  Methicillin-resistant *Staphylococcus aureus* (*MRSA*)                                                                                                                           4--19%                                     
  Enterobacter                                                                                                                                                                     9--38%                                     
  *E. coli*                                                                                                                                                                        6--52%                                     
  *Salmonella*                                                                                                                                                                                                                
  *Pseudomonas*                                                                                                                                                                    9--11%                                     
  *Clostridium*                                                                                                                                                                                                               
  *Bacteroides*                                                                                                                                                                                                               
  *Proteus*                                                                                                                                                                        14%                                        
  *Klebsiella*                                                                                                                                                                     14--17%                                    
  *Enterococcus*                                                                                                                                                                   12%                                        
  *Streptococcus*                                                                                                                                                                  14--21%                                    
  *Aspergillus*                                                                                                                                                                                                               
  Polymicrobial                                                                                                                                                                    40--56%                                    
  *Candida* species                                                                                                                                                                18--25%                                    
  Clinical features ([@CIT0002], [@CIT0003], [@CIT0007], [@CIT0008], [@CIT0012], [@CIT0023], [@CIT0015], [@CIT0016], [@CIT0018], [@CIT0019], [@CIT0029], [@CIT0031]--[@CIT0034])   Hemorrhagic shock                          18--100%
  Bright red blood per rectum                                                                                                                                                                                                 
  Coffee ground emesis                                                                                                                                                                                                        
  Herald bleeding                                                                                                                                                                                                             
  Melena                                                                                                                                                                                                                      
  Fever                                                                                                                                                                                                           30.3--87%   
  Sepsis                                                                                                                                                                                                                      
  Abscess                                                                                                                                                                          8--11%                                     
  Pulsating abdominal mass                                                                                                                                                         5--18.2%                                   
  Groin mass                                                                                                                                                                       12%                                        
  Limb ischemia                                                                                                                                                                    18.2--30%                                  
  Pseudo aneurysm                                                                                                                                                                                                             
  Abdominal pain                                                                                                                                                                   10--30%                                    
  Back pain                                                                                                                                                                        5--10%                                     
  Graft occlusion                                                                                                                                                                  21.2%                                      
  Femoral pseudoaneurysm                                                                                                                                                           5%                                         
  Weight loss                                                                                                                                                                      15.2%                                      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------ ----------- ----------

Clinical features {#S0002}
=================

A patient with a SAEF may present with upper or lower GI bleeding, sepsis, and/or hemodynamic instability ([Table 1](#T0001){ref-type="table"}). By far the commonest reported presentation is GI bleeding, which may vary in its presentation from herald bleeding to overt hemorrhagic shock ([@CIT0008], [@CIT0023], [@CIT0029]). Herald bleeding is an episode of transient or self-limiting early hemorrhage that may precede the ominous clinical hemorrhage. It may be present in approximately 20--75% of cases ([@CIT0008], [@CIT0023]). The onset of bleeding to the time of initial presentation may range from a few hours to a year (mean=3 days) ([@CIT0023]). The classic triad of GI bleeding, palpable abdominal mass, and abdominal pain is an infrequent clinical presentation ([@CIT0035]). After GI bleeding, sepsis or fever is the commonest presentation in patients with SAEF. In one study, GI bleeding occurred in 39/48 patients, whereas sepsis was the initial presentation in 20/48 patients ([@CIT0029]). When looking at the patients with sepsis; fever, leukocytosis, wound infection, septic embolism, and hypotension were the frequent presentations ([@CIT0013]). Other rare clinical features may include, groin infection, pseudoaneurysms, limb ischemia, retroperitoneal abscess, anorexia, malaise, and back pain ([@CIT0023], [@CIT0029], [@CIT0036]).

Establishing the diagnosis {#S0003}
==========================

The diagnosis of a SAEF is based on clinical grounds aided by readily available, non-invasive, and safer radiographic modalities such as computerized tomography (CT) scan ([@CIT0002]) ([Table 2](#T0002){ref-type="table"}). In addition to identifying the location of the conduit, CT scan may aid in identification of an infection or abscess if present ([@CIT0037]). The reported sensitivity and specificity of CT scan is approximately 90% (sensitivity 94% and specificity 85%) ([@CIT0026]). In one retrospective study, CT was useful in establishing the diagnosis of SAEF in 93% (26/28) of cases ([@CIT0023]). In a different study, abnormal CT findings were suggestive of SAEF in 92% (22/24) of patients and confirmatory in 8% (8/24) of patients ([@CIT0013]). CT scan findings that may be indicative of an AEF include: a gas shadow in or around the graft (sensitivity 40% and specificity 100%), focal wall inflammation and thickening, visible graft (sensitivity 22% and specificity 100%), soft tissue collection around the aorta \>5 mm (specificity 92% and sensitivity 90%), swelling or hematoma around the graft, intravenous contrast within the GI lumen or around the aorta, loss of calcification or tear in the aortic wall (specificity 75% and sensitivity 89%), pseudoaneurysm, and duodenal hematoma ([@CIT0002], [@CIT0009], [@CIT0032]).

###### 

Secondary aortoenteric fistula: diagnostic assessment

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------- ---------------------------------------------------------
  Diagnosis ([@CIT0002]--[@CIT0005], [@CIT0007], [@CIT0009], [@CIT0012], [@CIT0013], [@CIT0015], [@CIT0018], [@CIT0020], [@CIT0023], [@CIT0025], [@CIT0029]--[@CIT0034])   Exploratory laparotomy                                        Sensitivity and specificity 91--100%
                                                                                                                                                                           Computerized tomography scan                                  Sensitivity 40--100%; specificity 33.3--100%
                                                                                                                                                                           Computerized tomography angiography                           Sensitivity 33--100%
                                                                                                                                                                           EGD                                                           Sensitivity 10--80%, specificity 8.3--75%, accuracy 30%
                                                                                                                                                                           Radionuclide scanning with technetium-99-labeled leukocytes   Sensitivity 0%, specificity 0--80%
                                                                                                                                                                           Nuclear medicine RBC                                          Sensitivity 0%
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------- ---------------------------------------------------------

Esophagogastroduodenoscopy (EGD) is recommended in patients with a history of an AAA repair and/or upper GI bleeding ([@CIT0008]). An EGD may offer advantages in these particular patients when excluding other causes of GI bleeding ([@CIT0030]). Findings suggestive of SAEF on EGD include visible graft, bleeding, adherent clot, or ulcer or pulsatile mass ([@CIT0013], [@CIT0015]). Considerable variation may exist in diagnostic yield of EGD. This variation may partly be explained by operative technique or experience. In a case series of patients with AEF (SAEF=25), an EGD established the diagnosis in 6/15 patients (40%) ([@CIT0024]). In comparison, a study by Champion et al. ([@CIT0008]) revealed a better diagnostic yield with EGD -- 8/11 patients (73%). Because most of the AEFs occur in the third or the fourth parts of the duodenum, enteroscope or pediatric colonoscope may be utilized instead of the regular gastroscope to aid better visualization of distal duodenum and proximal jejunum ([@CIT0038], [@CIT0039]). Other modalities that may be used with variable success rate include magnetic resonance imaging, intravascular ultrasound, arteriography nuclear scans (e.g., tagged leukocyte scintigraphy), digital subtraction angiography, multidetector CT scan, and the single-photon emission computed tomography (for stent graft infection) ([@CIT0002], [@CIT0027], [@CIT0040]) ([Table 2](#T0002){ref-type="table"}).

The repair of SAEF {#S0004}
==================

Optimal outcomes of SAEF depend on maintaining hemodynamic stability by aggressive blood loss control, surgical repair of the underlying defect, infection control via empiric intravenous antibiotics, and revascularization and maintenance of perfusion to the lower limb ([@CIT0002], [@CIT0006]). Factors that may govern clinical outcomes depends on timeliness of the procedure; the revascularization approach (open vs. *in situ*); type of surgery (emergent vs. non-emergent); or the type of the graft utilized. Currently, there are no established guidelines for repair of the SAEF. The open approach entails graft excision and extra-anatomic bypass, whereas the endovascular approach consists of endovascular *in situ* graft replacement and partial or complete graft excision. The open approach may be advantageous in the setting of an underlying infection when an infected endograft can safely be excised thus eradicating the source of infection. In addition, simultaneous staged bowel repair can be performed in such cases. The endovascular repair offers shorter duration of surgery and hence requires minimal anesthesia. In addition, this surgical technique avoids complications associated with clamping of the aorta such as thrombosis, infection, and decreased perfusion of the colon and lower limbs ([@CIT0041]). In a multicenter retrospective study that compared endovascular (*n*=8) and open repair (*n*=17) for AEF (PAEF=1, SAEF=24), the overall morbidity was lower in patients who underwent endovascular repair when compared with the group that underwent an open repair (25 vs. 77% *p*=0.028) ([@CIT0016]). On the other hand, although the endovascular repair may have lower perioperative mortality and hospital stay, there may be a risk of infection relapse secondary to incomplete removal of the infected graft ([@CIT0012]). In one study, the risk of reinfection approached 44% (persistent, new, or recurrent infection) during a follow-up duration of 13 months ([@CIT0006]). In a different study, no difference in mortality or reinfection was observed between *in-situ* revascularization and extra-anatomic reconstruction ([@CIT0015]). Other factors that may influence mortality include emergent procedure, where 30-day mortality may be as high as 60% when compared to a non-emergent procedure (38%). Similarly, better outcomes were reported for a silver impregnated graft via *in situ* implantation when compared to the cohort who received a Dacron graft via extra-anatomic bypass (34.7 vs. 46.1%). In a recent report, *in situ* prosthetic graft excision and replacement with cryopreserved allograft was shown to have 25% postoperative mortality over the median duration of 31 months ([@CIT0017]).

Management of sepsis {#S0005}
====================

Broad-spectrum antibiotics that cover Gram-positive and Gram-negative organisms and anaerobes should be administered early. In addition, the source of infection, that is, the *in situ* aortic graft, has to be surgically excised, repaired, or replaced with the end goal of achieving prompt revascularization. Failure to treat sepsis may result in mortality in 60% of the cases ([@CIT0006]). The selection of antibiotics is determined by the results of blood, wound, intraoperative drainage, and tissue specimen culture. Intravenous vancomycin, piperacillin/tazobactam, and gentamicin may provide empiric coverage against the majority of identified organisms ([@CIT0025], [@CIT0017]). Antibiotics should be tailored after the culture and sensitivity results. Intravenous antibiotics should be continued for at least 4--6 weeks, followed by long-term oral antibiotics such as amoxicillin--clavulanate, levofloxacin, or trimethoprim--sulfamethoxazole ([@CIT0031], [@CIT0033]). The C-reactive protein may help guide the duration of antibiotic and monitor the response of therapy ([@CIT0028]).

Perioperative complications {#S0006}
===========================

Complications may depend on type of revascularization and can occur during the intraoperative period, the perioperative period, or at several months follow-up. Sepsis remains a life-threatening complication following endovascular AEF repair ([@CIT0042]). Other life-threatening complications include uncontrolled bleeding, multiorgan failure, acute coronary event, limb ischemia leading to gangrene or amputation, liver failure, and acute respiratory failure ([@CIT0004], [@CIT0029]). In one study, extra-anatomic bypass failure occurred in 18.2% (6/33 of cases), lower extremity amputation in 9.1% (3/33 of cases), and extra-anatomic bypass infection in 15% (5/33 of cases) ([@CIT0013]). When comparing complication rate between open \[(*n*=17) vs. endovascular repair (*n*=8)\], multiple organ failure occurred in 29% (5/17 cases) in the open group and none in the endovascular group. Recurrent bleeding occurred in 12% (2/17 cases) in the open group and none in the endovascular group. Lower extremity ischemia occurred in the 29% (5/17 cases) in the open group and 13% (1/8 cases) in the endovascular group. Loss of the lower extremity occurred in 12% (2/17 cases) in the open group and 13% (1/8 cases) in the endovascular group. Last, mortality was found to be higher in the open group 35% (6/17) when compared to the endovascular group 0% ([@CIT0016]). These results may favor the use of endovascular repair over open repair.

Predictors of recurrent sepsis and overall survival {#S0007}
===================================================

Clinical variables may prognosticate better or worse outcomes, and can provide clinicians and surgeons with goal-directed management for high-risk cases. Kakkos et al. ([@CIT0016]) reported that patients taking two antibiotics at the time of discharge had a lower incidence of sepsis at 2 years (0%) when compared to a single antibiotic (63%) or no antibiotic regimen (100%). In a different study, a lower survival was reported in patients who had fever at the time of presentation \[fever vs. no fever (11% vs. 52%, *p*=0.04) or preoperative sepsis (24 vs. 50% *p*=0.32)\]. In another study, intraoperative factors associated with early mortality after repair included hemodynamic instability, the need for blood transfusion, and aortic clamp placement above the renal arteries ([@CIT0023]). In a systematic review, preoperative infection \[OR 9.36 (2.24--39.12)\] and any complication after endovascular procedure \[OR 80.75 (8.20--794.944)\] were identified as predictors of adverse outcomes in the univariate analysis. Furthermore, patients in the infection group (persistent or recurrent) had a shorter (1 month) survival when compared to patients without infection (*p*=0.042) ([@CIT0006]).

The type of grafts utilized during the surgical procedure may also affect clinical outcomes. Cryopreserved grafts compared to fresh allografts were shown to have reduced risk of endoleak, rupture, and other graft-related complications ([@CIT0041]). Successful outcomes have been reported for rifampin-soaked endografts in a few instances ([@CIT0043]). Surgical complications may further contribute to morbidity.

The SAEF may be associated with post-implantation syndrome (PIS) -- a frequent occurrence associated with aortic graft placement. The PIS is characterized by fever, leukocytosis, and/or hypercoagulability without a source of infection confirmed by negative culture. This may contribute to morbidity and, therefore, result in a prolonged hospital stay ([@CIT0044], [@CIT0045]). Thus, the presence of infection and hemodynamic instability portends poor prognosis and may necessitate aggressive management.

Prognosis of SAEF {#S0008}
=================

The prognosis in patients with SAEF may depend on the hemodynamic status of the patient at presentation, the operative technique performed, and time to surgical exploration. A delay in surgical exploration may increase mortality, whereas an uncorrected SAEF is almost always fatal ([@CIT0012]). In one report, the mortality rate at the first month reached 45.8%, 34% at 3 years, and 27.4% at 5 years ([@CIT0029]). In a different study, there were six perioperative and three mortalities after 1 month with an overall mortality rate of 27.2% over the course of 4.4±3.7 years ([@CIT0013]). Similarly, in a different report, the mortality rate approached 40% in the first month ([@CIT0024]). Nevertheless, the reported survival seems to be improving over the years. In a recent report by Schoell et al. ([@CIT0017]), 1-month, 1-year, and 5-year survival was 75, 70, and 66%, respectively. These results are promising and suggest that a SAEF is not as ominous as previously thought.

Conclusions {#S0009}
===========

A SAEF should be ruled out in a patient presenting with GI bleeding with prior history of AAA repair. Early recognition of symptoms may avoid the untoward hemodynamic instability. The management of SAEF requires a multidisciplinary approach involving the intensivists, vascular surgeons, and gastroenterologists. The use of CT scan may assist in establishing an early diagnosis. Endovascular approach in selected cases may ameliorate complications associated with open revascularization. Future research direction exploring the benefit of various types of endograft and surgical techniques may hold promise for providing better care to patients with this debilitating clinical entity.
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